Amundi Has $98.22 Million Stock Holdings in Waters Corporation $WAT

Key Points

• Amundi increased its stake in Waters Corporation (NYSE:WAT) by 1.5%, owning 284,590 shares valued at approximately $98.2 million.
• Waters reported $2.95 earnings per share for the last quarter, surpassing estimates, with revenues reaching $771.33 million, a year-over-year increase of 8.8%.
• Wall Street analysts have mixed opinions on Waters, with target prices ranging from $315 to $465, and a consensus rating of "Hold".

Amundi lifted its stake in Waters Corporation (NYSE:WAT - Free Report) by 1.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 284,590 shares of the medical instruments supplier's stock after acquiring an additional 4,149 shares during the period. Amundi owned 0.48% of Waters worth $98,218,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in WAT. Olde Wealth Management LLC acquired a new position in Waters during the first quarter valued at approximately $25,000. Zions Bancorporation National Association UT acquired a new position in Waters in the 1st quarter valued at $28,000. IFP Advisors Inc grew its stake in Waters by 118.9% in the 1st quarter. IFP Advisors Inc now owns 81 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 44 shares during the last quarter. Whipplewood Advisors LLC raised its holdings in Waters by 5,200.0% in the 1st quarter. Whipplewood Advisors LLC now owns 106 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 104 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Waters during the 1st quarter worth $41,000. Institutional investors own 94.01% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company lowered their price target on Waters from $330.00 to $315.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 5th. UBS Group restated a "neutral" rating on shares of Waters in a research note on Tuesday, July 15th. Bank of America lifted their price target on Waters from $370.00 to $375.00 and gave the stock a "neutral" rating in a research report on Thursday, June 26th. Robert W. Baird reduced their price objective on Waters from $374.00 to $352.00 and set an "outperform" rating for the company in a research report on Wednesday, July 16th. Finally, Wall Street Zen downgraded shares of Waters from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $378.73.

Waters Stock Performance

Shares of NYSE:WAT traded up $9.92 during trading on Thursday, hitting $302.95. 384,137 shares of the stock were exchanged, compared to its average volume of 586,576. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $423.56. The company has a market capitalization of $18.03 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 2.73 and a beta of 1.07. The company's fifty day simple moving average is $300.75 and its 200-day simple moving average is $333.97. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.22 and a current ratio of 1.75.

Waters (NYSE:WAT - Get Free Report) last issued its earnings results on Monday, August 4th. The medical instruments supplier reported $2.95 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.02. The business had revenue of $771.33 million during the quarter, compared to analyst estimates of $745.96 million. Waters had a return on equity of 38.60% and a net margin of 21.71%.Waters's revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.63 earnings per share. Waters has set its Q3 2025 guidance at 3.150-3.250 EPS. FY 2025 guidance at 12.950-13.050 EPS. Sell-side analysts expect that Waters Corporation will post 12.86 EPS for the current fiscal year.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.